{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/migraine/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"52e6d993-e2b2-59c3-920f-27f34a7ec2eb","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field c2ef7549-2820-415f-b8be-c8292557b97c --><h2>Changes</h2><!-- end field c2ef7549-2820-415f-b8be-c8292557b97c -->","summary":null,"htmlStringContent":"<!-- begin item 4977585b-3443-4cdb-bac7-7f2016a190d6 --><!-- begin field 8e0fd80b-6fa3-4988-8c6b-96481fc5a932 --><p><strong>October 2020</strong> — minor update. Dysphagia added as an adverse effect of triptans in line with the revised manufacturer's SPC.</p><p><strong>July 2020</strong> — minor update. The adverse effects of topiramate have been updated in line with the revised manufacturer's SPC.</p><p><strong>April 2019</strong> — reviewed. A literature search was conducted in March 2019 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of the topic. Minor changes to the recommendations have been made in line with updated guidance from the National Institute for Health and Care Excellence [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">NICE, 2012 (updated 2015)</a>] and the Scottish Intercollegiate Guidelines Network [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">SIGN, 2018</a>].</p><!-- end field 8e0fd80b-6fa3-4988-8c6b-96481fc5a932 --><!-- end item 4977585b-3443-4cdb-bac7-7f2016a190d6 -->","topic":{"id":"b2a19577-fc3a-5b75-948b-7c86424dba8f","topicId":"8d5c9fe8-c317-4160-9aa5-50f3a0456472","topicName":"Migraine","slug":"migraine","lastRevised":"Last revised in October 2020","chapters":[{"id":"f5de766d-b899-5cb2-978f-7194e0cbeaf4","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"57045461-bc73-53e8-9968-49ab778a037a","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"32406f3a-91ba-5801-9ef0-87ad7d9b3133","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"52e6d993-e2b2-59c3-920f-27f34a7ec2eb","slug":"changes","fullItemName":"Changes"},{"id":"9560b149-423e-5bf5-8239-ae3f4bc97616","slug":"update","fullItemName":"Update"}]},{"id":"f6c897d2-fd52-5c54-a91b-1b366dced50e","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"058608e6-7b11-54ed-9d12-69b94ea020cf","slug":"goals","fullItemName":"Goals"},{"id":"95d8aa4b-0bce-5da9-b56a-a612d637a001","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"f9b5443b-1c38-5f3c-be42-3e7fffa429e3","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"d5644cb5-763c-596c-8c47-919fec89ce47","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"92308844-16f7-5eeb-9c0a-ad97a07896ec","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"b97a29bb-bac7-5bc8-907c-210d887086f2","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"986db6f6-7568-5e6e-8095-5ce116d22307","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"b6d1719e-8f6a-509b-90d2-7d1f38e19b05","slug":"definition","fullItemName":"Definition"},{"id":"e35d9975-5859-5454-9539-fab1a8ca6a43","slug":"causes","fullItemName":"Causes"},{"id":"3d8350c0-8bc5-5793-a577-411bc703d36f","slug":"prevalence","fullItemName":"Prevalence"},{"id":"eea7fb2e-ce45-5fa7-9ff5-5399f8305dd7","slug":"prognosis","fullItemName":"Prognosis"},{"id":"ad3ec7a1-a418-5232-b554-b202784e3f46","slug":"complications","fullItemName":"Complications"}]},{"id":"23b2a2ec-5694-51eb-97af-5e80f8d0b792","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"86e96919-af81-53dc-805a-36533fa27637","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"1b00b35a-f7c5-5dc3-bd7d-6e72a973af14","slug":"assessment","fullItemName":"Assessment"},{"id":"33c2a435-70da-50e9-b336-2d81b68f99c9","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"1ece6bbf-1986-5392-be1d-427e9603f26a","fullItemName":"Management","slug":"management","subChapters":[{"id":"eb14162e-c87a-5ca7-8eda-4acb5c336298","slug":"adults","fullItemName":"Scenario: Adults"},{"id":"3bced75d-3a79-536f-976d-875a40bf1a8d","slug":"young-people-aged-12-17-years","fullItemName":"Scenario: Young people aged 12-17 years"},{"id":"604f5c24-3920-5626-893b-9c27575decc6","slug":"pregnant-or-breastfeeding-women","fullItemName":"Scenario: Pregnant or breastfeeding women"}]},{"id":"8e2844f3-6843-5776-a5a1-59b0cabc5b93","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"d1661673-77b9-587b-94ce-e5b6ff9de8c5","slug":"drugs-for-acute-migraine","fullItemName":"Drugs for acute migraine"},{"id":"b69cd3a2-8118-552d-ba35-c7db1a498617","slug":"drugs-for-the-prevention-of-migraine","fullItemName":"Drugs for the prevention of migraine"}]},{"id":"daf55050-4154-5b6d-b8ab-0f86775d1038","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"0fbeb3e2-26df-5d63-a045-8af31aed07ef","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"88a22f7c-7eb4-5b57-a406-ab204723d6c0","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"596ed3f2-0ac4-5fd9-9046-b304311543ee","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"c4597510-7ec3-5f98-b5a5-3ef55cd51b5e","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"79a12dcb-038c-5fd4-a311-648c3ee61102","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"41030681-d726-58c4-b509-29748e404597","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"9a8a7e48-db76-50eb-a585-96fe1b4a5977","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"32406f3a-91ba-5801-9ef0-87ad7d9b3133","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"132bfba2-adbd-512a-88dc-1aaa3c0fdcbc","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field d8442e7b-e48d-4848-95c3-8070ae75067c --><h3>Previous changes</h3><!-- end field d8442e7b-e48d-4848-95c3-8070ae75067c -->","summary":null,"htmlStringContent":"<!-- begin item 4af0b22d-e704-4547-9968-cc6fb0706647 --><!-- begin field b7c8f93c-a835-413a-a988-8daf5b834f53 --><p><strong>October 2018</strong> — minor update. New product availability added.</p><p><strong>February 2018</strong> — minor update. SIGN (2018) Pharmacological management of migraine.</p><p><strong>December 2017</strong> — minor update. Added information about fetal malformations and effectiveness of hormonal contraceptives as an effect of topiramate.</p><p><strong>September 2017</strong> — minor update. Added information about hyperammonemia as an adverse effect of topiramate.</p><p><strong>August 2017</strong> — minor update. More accurately worded text in CG150, in the management section for 'Acute treatment of young people'.</p><p><strong>May 2016</strong> — minor update. Updated text to reflect the current advice from the Medicines and Healthcare products Regulatory Agency (MHRA) on domperidone.</p><p><strong>October 2015</strong> — minor update. Prescribing information has been updated to include intestinal ischemia as a possible adverse effect of almotriptan.</p><p><strong>May 2014</strong> — minor update. Update to the text to reflect recent advice issued by the European Medicines Agency regarding the dose and length of treatment with domperidone.</p><p><strong>December 2013</strong> — minor update. The link to the UKMI drugs in lactation website has been removed as this no longer exists.</p><p><strong>September 2013</strong> — minor update. Update to the text to reflect current recommendations regarding metoclopramide.</p><p><strong>January to August 2013</strong> — reviewed. A literature search was conducted in January 2013 to identify evidence-based guidelines, UK policy, systematic reviews, and key RCTs published since the last revision of this topic. Recommendations from the guideline Headache - Diagnosis and management of headache in young people and adults commissioned by the National Institute for Health and Care Excellence (NICE) have been added.</p><p><strong>February 2013</strong> — minor update. The 2013 QIPP options for local implementation have been added to this topic.</p><p><strong>November 2012</strong> — minor update. The links to the electronic medicines website (www.medicines.org.uk) have been updated.</p><p><strong>January 2012</strong> — minor update. McNeil Products Ltd, in collaboration with the Medicines and Healthcare products Regulatory Agency (MHRA), has published new safety data regarding the association of domperidone with an increased risk of serious ventricular arrhythmias or sudden cardiac death. This topic has been updated to reflect their advice on dosing, adverse effects, and drug interactions. Issued in February 2012.</p><p><strong>July 2011</strong> — minor update. More exact paracetamol dosing for children has been introduced by the Medicines and Healthcare products Regulatory Agency. Prescriptions have been updated to reflect the revised dosing. Issued in July 2011.</p><p><strong>May 2011</strong> — minor update. The 2010/2011 QIPP options for local implementation have been added to this topic. Issued in June 2011.</p><p><strong>October 2010</strong> — topic structure revised to ensure consistency across CKS topics — no changes to clinical recommendations have been made.</p><p><strong>March 2010</strong> — minor update. Advice from the NICE guideline Depression in adults with a chronic physical health problem regarding drug interactions between antidepressants and triptans has been added. Issued in March 2010.</p><p><strong>July to December 2008</strong> — converted from CKS guidance to CKS topic structure. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence. The scope of this CKS topic has been expanded to cover the management of children with migraine. Prescriptions for topiramate have been removed as this would be initiated by a specialist.</p><p><strong>September 2008</strong> — minor correction to Changes section. Issued in September 2008.</p><p><strong>July 2006</strong> — updated. Topiramate is now licensed for the prophylaxis of migraine in adults and prescriptions have been added for use under specialist supervision. Issued in July 2006.</p><p><strong>January 2006</strong> — minor update. Black triangle removed from almotriptan. Issued in February 2006.</p><p><strong>October 2005</strong> — minor technical update. Issued in November 2005.</p><p><strong>July 2005</strong> — updated text discussing nonsteroidal anti-inflammatory drugs (NSAIDs) in the Medicines management and Prescribing points sections. Issued in July 2005.</p><p><strong>January 2005</strong> — rewritten. Validated in March 2005 and issued in April 2005.</p><p><strong>December 2001</strong> — rewritten. Validated in March 2002 and issued in April 2002.</p><p><strong>September 1998</strong> — written.</p><!-- end field b7c8f93c-a835-413a-a988-8daf5b834f53 --><!-- end item 4af0b22d-e704-4547-9968-cc6fb0706647 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}